CARRA selects Emmes as CRO partner for 70-site pediatric rheumatology registry
CARRA selected Emmes as its contract research organization partner for the CARRA Registry & Biorepository, covering 70 clinical sites and more than 16,000 participants. The move shifts CRO operations for observational registry NCT02418442 to a Functional Service Provider model.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
The Childhood Arthritis and Rheumatology Research Alliance (CARRA) selected Emmes as its contract research organization (CRO) partner under a Functional Service Provider (FSP) model for the CARRA Registry & Biorepository, spanning 70 clinical sites across the United States and Canada with more than 16,000 enrolled participants, Emmes said. Under the engagement, Emmes provides Scientific Support, Project Management, Data Management, Statistical Support, Clinical Operations, Safety, and Regulatory functions alongside capabilities CARRA is bringing in-house, plus targeted support for biopharma partner studies that use registry data and sites, the release states. The shift moves operational support for the observational pediatric rheumatic disease registry (NCT02418442), which enrolls children and young adults with juvenile idiopathic arthritis (JIA) and related diseases, into a hybrid operating model between CARRA and Emmes, the release and study record show.
| Party | Founded | Based |
|---|---|---|
| CARRA | 2002 | spanning North America |
| Emmes | 1977 | Rockville, Md. |
CARRA
-
- Founded
- 2002
- Based
- spanning North America
Emmes
-
- Founded
- 1977
- Based
- Rockville, Md.
From the Emmes release of Nov. 17, 2026, via PR Newswire.
Why it matters
In the protocol for NCT02418442, sponsored by Duke University, the Duke Clinical Research Institute (DCRI) is the CARRA Clinical and Data Coordinating Center (CDCC), the ClinicalTrials.gov record shows. The protocol cites letters from the United States Food and Drug Administration (FDA) to CARRA on 21 December 2010 and 9 December 2011 stating that data from a consolidated disease-based registry offers a path for individual companies to satisfy post-marketing requirements and commitments and obviate the need for an individual product registry. Traditional exposure-based post-marketing registries of single drugs for JIA, systemic lupus erythematosus and other rheumatic diseases suffer from sample sizes too small to detect uncommon safety events, lack unexposed comparators, and follow patients for too short a duration to evaluate delayed adverse events, the study record notes. CARRA and Emmes stated that the new hybrid operating model is designed to expand site participation, modernize data capture, and strengthen infrastructure supporting both CARRA-led and biopharma-sponsored research.
CARRA Registry transition and scope
Emmes and CARRA announced the CRO partnership on Nov. 17, 2026, with Emmes already working alongside CARRA to prepare the transition to the hybrid operating model, which is expected to be completed in January 2028, Emmes said.
The CARRA Registry & Biorepository draws on 70 clinical sites across the United States and Canada and tracks more than 16,000 enrolled participants with pediatric rheumatic diseases, including:
- juvenile idiopathic arthritis (JIA)
- lupus and related conditions
- juvenile dermatomyositis (JDM)
- scleroderma
Under the FSP model, Emmes is set to assume ongoing support, enhancement and maintenance of the registry while complementing functions CARRA is bringing in-house, the release states. Emmes is also tasked with providing targeted support for biopharma-sponsored studies that draw on CARRA Registry data and its network of clinical sites, according to the release.
"With Emmes as our next generation Registry & Biorepository partner, we are well positioned to continue research that improves the lives of children with rheumatic disease," CARRA Chief Executive Officer Rachel Myslinski said in the release. Paul VanVeldhuisen, President, Public Sector and Chief Scientific Officer at Emmes, cited "nearly four decades of registry experience."
Registry design and enrollment under NCT02418442
The original CARRA Legacy Registry (Protocol Number CRNT_REGST01) was established in 2010, and the continuing prospective observational cohort study registered as NCT02418442 started in 2015 and remains recruiting, the ClinicalTrials.gov record shows.
Protocol details listed in NCT02418442 include:
- Enrollment target: estimated 20,000 participants across participating CARRA sites
- Duration: prospective follow-up for a goal of 10 years per participant, with study completion estimated in 2028
- Inclusion and exclusion criteria: onset of rheumatic disease prior to age 16 years for JIA and prior to age 19 years for all other rheumatic diseases, excluding individuals greater than 21 years of age at enrollment
- Biosample collection: active collection retaining samples with DNA for a subset of registry participants
- Safety review: systematic tracking of serious adverse events and protocol-defined events of special interest, with selected events such as malignancies adjudicated by a panel of experts through medical record review
In addition to safety monitoring, the registry collects the data for CARRA Consensus Treatment Plan (CTP) comparative effectiveness studies, such as the FROST project comparing 4 systemic JIA treatment strategies, the study record states.
CARRA and Emmes background
Founded in 2002, CARRA is a 501(c)(3) nonprofit investigator-led research network spanning North America that maintains the CARRA Registry as a source of longitudinal data on pediatric rheumatic disease outcomes, the release states.
Emmes, part of Emmes Group and based in Rockville, Md., was founded in 1977 and has supported more than 2,000 clinical studies and registries across government, nonprofit, academic and biopharmaceutical partners, including pediatric patient registries such as NAPRTCS, SPLIT and the Collaborative Islet Transplant Registry (CITR), Emmes said.